SMPD1 Gene

📖 Wiki Page

gene720 wordssynced 2026-04-02

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SMPD1 Gene - Acid Sphingomyelinase</th>
</tr>
<tr>
<td class="label">infobox</td>
<td>[@thurberg2005]</td>
</tr>
<tr>
<td class="label">SMPD1 Gene</td>
<td>[@hex2003]</td>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SMPD1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11p15.4</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6609</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>257200</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166311</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P17405</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Niemann-Pick Disease Type A/B, Acid Sphingomyelinase Deficiency (ASMD)</td>
</tr>
</table>

Pathway Diagram

...

SMPD1 Gene

Pathway Diagram

Mermaid diagram (expand to render)

Introduction

Smpd1 Gene Acid Sphingomyelinase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

SMPD1 (Sphingomyelin Phosphodiesterase 1) encodes acid sphingomyelinase (ASM), a lysosomal enzyme that hydrolyzes sphingomyelin to ceramide and phosphorylcholine. Mutations in SMPD1 cause Niemann-Pick disease types A and B, lysosomal storage disorders characterized by sphingomyelin accumulation in macrophages throughout the reticuloendothelial system. [@pentchev1984]

Function

The SMPD1 gene encodes acid sphingomyelinase (ASM), a lysosomal hydrolase enzyme that catalyzes the hydrolysis of sphingomyelin to ceramide and phosphorylcholine. This enzyme plays a critical role in lipid metabolism and cellular signaling within the lysosomal compartment.

ASM is synthesized as a preproenzyme in the endoplasmic reticulum, processed through the Golgi apparatus, and targeted to lysosomes via mannose-6-phosphate receptor-mediated trafficking. The mature enzyme is a 75 kDa glycoprotein consisting of an N-terminal catalytic domain and a C-terminal domain.

Key Functions

Lipid Catabolism: Hydrolyzes sphingomyelin, a major membrane phospholipid, within lysosomes
Ceramide Generation: Produces ceramide, a bioactive lipid that regulates apoptosis, cell cycle arrest, and stress responses
Membrane Trafficking: Participates in endocytic and autophagic pathways
Signal Transduction: Ceramide generated by ASM acts as a second messenger in various signaling cascades

Disease Associations

Niemann-Pick Disease Type A and B

Niemann-Pick disease type A (NPD-A) and type B (NPD-B) are caused by autosomal recessive mutations in the SMPD1 gene, resulting in deficient or absent acid sphingomyelinase activity.

NPD-Type A: Severe infantile neurovisceral form with neurodegeneration, hepatosplenomegaly, and early mortality (typically by age 2-3)
NPD-Type B: Chronic visceral form with primarily systemic manifestations, often surviving into adulthood

Neurodegeneration in ASMD

While NPD-A/B are classically lysosomal storage disorders, the accumulated sphingomyelin and secondary ceramide elevation contribute to neurodegeneration through:

Lysosomal Dysfunction: Accumulated lipids impair lysosomal function and [autophagy](/entities/autophagy)

Oxidative Stress: Ceramide accumulation promotes [ROS](/entities/reactive-oxygen-species) generation

[Apoptosis](/entities/apoptosis) Signaling: Ceramide is a pro-apoptotic molecule that activates caspase-dependent cell death

Neuroinflammation: Lipid accumulation activates [microglia](/entities/microglia) and [astrocytes](/entities/astrocytes)

Potential Links to Other Neurodegenerative Diseases

Research suggests altered sphingolipid metabolism may play roles in:

Alzheimer's Disease: [Aβ](/proteins/amyloid-beta)-induced ceramide elevation and ASM activation
Parkinson's Disease: Altered sphingolipid profiles in PD patients
Multiple Sclerosis: ASM deficiency protective in mouse models

Expression

SMPD1 is expressed ubiquitously with highest expression in:

Liver
Spleen
Lung
Brain ([neurons](/entities/neurons) and glia)
Fibroblasts

In the brain, ASM is expressed in neurons, astrocytes, [microglia](/cell-types/microglia-neuroinflammation), and oligodendrocytes, with particular importance in white matter tracts.

Therapeutic Targeting

Enzyme Replacement Therapy

Olipudase alfa (Xenpozyme): FDA-approved recombinant human ASM (rh-ASM) for ASMD
Reduces sphingomyelin accumulation in liver and spleen
Does not cross the [blood-brain barrier](/entities/blood-brain-barrier), limiting effects on CNS manifestations

Small Molecule Approaches

Substrate reduction therapy: Reduce sphingomyelin synthesis
Ceramide analogs: Modulate ceramide-mediated signaling
Gene therapy: AAV-vector delivery to CNS (experimental)

Research Directions

Brain-targeted enzyme replacement
Small molecule chaperones to enhance mutant ASM activity
Gene therapy approaches for CNS involvement

External Links

[NCBI Gene: SMPD1](https://www.ncbi.nlm.nih.gov/gene/6609)
[UniProt: P17405](https://www.uniprot.org/uniprot/P17405)
[OMIM: 257200](https://www.omim.org/entry/257200)
[GeneTests: SMPD1](https://www.ncbi.nlm.nih.gov/books/NBK1372/)

Background

The study of Smpd1 Gene Acid Sphingomyelinase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Schuchman EH, Desnick RJ, (2017) (2017)

Pentchev PG, et al, (1984) (1984)

Thurberg BL, et al, (2005) (2005)

Wasserstein MP, et al, (2019) (2019)

HeX, et al, (2003) (2003)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: SMPD1

Pathway Diagram

The following diagram shows the key molecular relationships involving SMPD1 Gene - Acid Sphingomyelinase discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

SciDEX Links

Related Hypotheses

[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — score 0.92; target SMPD1; neurodegeneration.
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — score 0.92; target CYP46A1; neurodegeneration.
[SASP-Driven Aquaporin-4 Dysregulation](/hypothesis/h-807d7a82) — score 0.78; target AQP4; neurodegeneration.
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — score 0.70; target P2RY12; neurodegeneration.

Related Analyses

[Lipid raft composition changes in synaptic neurodegeneration](/analyses/SDA-2026-04-01-gap-lipid-rafts-2026-04-01)
[Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analyses/SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402)
[How do sphingomyelin/ceramide ratios specifically regulate BACE1 clustering and activity in synaptic vs non-synaptic lipid rafts?](/analyses/SDA-2026-04-15-gap-debate-20260410-112819-e40e0fa2)

📖 View canonical wiki page →

SMPD1 Gene - Acid Sphingomyelinase

SMPD1 Gene

Pathway Diagram

SMPD1 Gene

Pathway Diagram

Introduction

Overview

Function

Key Functions

Disease Associations

Niemann-Pick Disease Type A and B

Neurodegeneration in ASMD

Potential Links to Other Neurodegenerative Diseases

Expression

Therapeutic Targeting

Enzyme Replacement Therapy

Small Molecule Approaches

Research Directions

See Also

External Links

Background

References

Related Hypotheses

Pathway Diagram

SciDEX Links

Related Hypotheses

Related Analyses